Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation, in Phase 2 testing in Japan and eligible for early conditional approval for the treatment of critical limb ischemia; CLBS16 (formerly known as CLBS14-CMD), subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. for the treatment of coronary microvascular dysfunction; and CLBS14 (formerly known as CLBS14-NORDA), recipient of a RMAT designation in the U.S.A. and for which we are in preparations to commence a Phase 3 clinical trial in no option refractory disabling angina.

**INVESTMENT HIGHLIGHTS**

**Late-stage therapeutics development company**
- Pioneering advancements of cell therapies in cardiovascular disease
- Three principal development programs; 2 designated “breakthrough”*
  - CD34+ cells for ischemic repair (CLBS12*, CLBS14*, CLBS16)

**CD34+ cell therapy technology platform includes nearer-term commercial opportunities**
- CLBS12 is an ongoing critical limb ischemia study in Japan with SAKIGAKE designation for expedited review and eligible for early conditional approval
- CLBS14 is in Phase 3 development in the USA for no option refractory disabling angina
- CLBS16 is an ongoing proof-of-concept Phase 2 study in the USA for coronary microvascular dysfunction and is supported by a grant from the NIH

**Financially stable and debt-free**
- Strong balance sheet (~$38 million cash as of March 31, 2019)
- Low operating cash burn (cash projected through 2Q 2020)

**Dedicated and highly motivated leadership team with extensive experience in biopharmaceutical development**

**MARKET SNAPSHOT**

<table>
<thead>
<tr>
<th>Ticker Symbol</th>
<th>CLBS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>NASDAQ</td>
</tr>
<tr>
<td>52-Week Price Range</td>
<td>$2.77 - $11.65</td>
</tr>
<tr>
<td>Shares Outstanding (3/31/19)</td>
<td>~10.4 mil</td>
</tr>
<tr>
<td>Cash &amp; Investments (3/31/19)</td>
<td>~$38 mil</td>
</tr>
<tr>
<td>Fiscal Year-End</td>
<td>December 31</td>
</tr>
</tbody>
</table>

**POTENTIAL VALUE CREATING MILESTONES**

- **2Q 2019**: Finalize CLBS14 clinical plan with FDA
- **2H 2019**: Announce ESCaPE-CMD Phase 2 study topline data
- **2H 2019**: Complete enrollment in CLBS12 Phase 2 study
- **2H 2019**: Initiate CLBS14 pivotal Phase 3 study
- **1H 2020**: Announce CLBS12 Phase 2 study topline data
The potential of Tregs as a therapeutic platform differentiates itself from available therapeutics and almost all other investigational agents in development through:

- Disease modification via restoration of immune tolerance as the most proximal/root cause of the autoimmune disease pathways, in contrast to targeting less pivotal and redundant downstream effects
- Freedom from indiscriminate immune suppression of vital effector functions of the immune system
- Specific homing to disease affected organs, thus targeting tolerance to where it is needed most

### CD34+ CELL THERAPY PLATFORM

- CD34 is a cell surface protein that identifies a subset of mononuclear cells in the bone marrow and circulation
- CD34+ cells are pre-programmed vascular repair cells that promote angiogenesis of the microvasculature. Caladrius’ proprietary platform technology selects and delivers a potent, concentrated population of the patient’s own CD34+ cells for optimal therapeutic benefit

### T REGULATORY CELL THERAPY PLATFORM

- Caladrius’ T regulatory cell technology is based on autologous ex vivo expanded polyclonal T regulatory cells, which are functionally enhanced prior to re-introduction to the patient
- Therapeutic T regulatory cells (Tregs) are thought to be active in the treatment of autoimmune diseases in which deficient Treg activity results in the patient’s immune system attacking the body’s own beneficial tissues
- Caladrius’ technology to enhance autologous Treg number and function leverages the native immune regulatory mechanisms, offering a path to true disease modification

## Pre-clinical Phase 1 Phase 2 Phase 3

<table>
<thead>
<tr>
<th>CD34+ Cell Therapy Platform (Ischemic Repair)</th>
<th>CLBS12 Critical Limb Ischemia</th>
<th>CLBS16 Coronary Microvascular Dysfunction</th>
<th>CLBS14 No Option Refractory Disabling Angina</th>
</tr>
</thead>
</table>

Results of comprehensive analysis of 1-year patient level data in conjunction with 2-year follow-up data (end 2019) will determine next development steps.